M
utations in the hepatocyte nuclear factor (HNF)-1␣ gene cause the most common form of maturity-onset diabetes of the young (MODY), type 3 (1) . Clinical studies in humans indicate that ␤-cell dysfunction in MODY3 patients leads to a defect in glucose-stimulated insulin secretion that is responsible for chronic hyperglycemia (2) . Mice lacking the Hnf-1␣ gene (3, 4) also have a dramatic reduction in insulin secretory response to glucose. Insulin secretion from islets of Hnf-1␣ Ϫ/Ϫ mice is blunted in response to glucose and other glycolytic stimuli but normal in response to non-nutrient secretagogues such as potassium (5) . Furthermore, the expression of GLUT2 and the glycolytic enzymes glucokinase and liver pyruvate kinase are reduced in pancreatic islets of Hnf-1␣ Ϫ/Ϫ mice compared with wild-type mice (6) . Therefore, a defect in the ␤-cell glycolytic pathway contributes to diabetes in Hnf-1␣ Ϫ/Ϫ mice and MODY3 patients. Despite the profound reduction of insulin responses to glucose stimulation, MODY3 patients have been shown to be hypersensitive to the actions of sulfonylurea drugs with symptoms of hypoglycemia developing 60 -90 min after as little as 0.5 mg glibenclamide orally (7) (8) (9) . Hypersensitivity to sulfonylureas can occur in both early and late stages of the disease as well as in glucose-tolerant or diabetic subjects with HNF-1␣ mutations. Furthermore, increased sensitivity to glibenclamide has been shown to cosegregate with mutation hot spot P291fsinsC in one Norwegian family, suggesting that a pharmacogenetic mechanism may be responsible for the altered pharmacological response to glibenclamide treatment (8) .
Sulfonylureas cause hypoglycemia by stimulating insulin release from ␤-cells. The effects of sulfonylureas are initiated by drug binding to the ATP-sensitive K ϩ (K ATP ) channel, a complex that consists of two subunits: the sulfonylurea receptor (SUR1) and an inward rectifier channel protein (Kir6.2), located in the plasma membrane of ␤-cells (10, 11) . Interaction of sulfonylurea and receptor induces membrane depolarization, activation of voltagegated Ca 2ϩ channel, and degranulation of insulin-containing vesicles (12) . We have recently shown that the gene expression of Sur1 and Kir6.2 are normal in islets of Hnf-1␣ Ϫ/Ϫ mice (6). Thus, although ␤-cell K ATP channels play a critical role in the regulation of glucose-and sulfonylurea-induced insulin secretion, their expression is not regulated by Hnf-1␣ and is unlikely to be directly involved in the hypersensitivity to sulfonylureas.
HNF-1␣ is expressed in pancreatic islets, liver, kidney, and intestine. Liver and kidney play a significant role in the detoxification of drugs. Therefore, HNF-1␣ gene mutations could lead to liver or kidney dysfunction altering the pharmacokinetics of sulfonylureas in MODY3 patients. We have postulated that the unusual sensitivity to the hypoglycemic effect of sulfonylureas in these patients could be due to an impairment of drug elimination/metabolism. To test our hypothesis, we have used a murine model of MODY3, the Hnf-1␣-deficient (Hnf-1␣ Ϫ/Ϫ ) mice, and glibenclamide (1-{4-[2-(5-chloro-2-methoxybenzamido)ethyl]-benzenesulfonyl}-3-cyclohexylurea), a second-generation sulfonylurea compound. Glibenclamide is metabolized in the liver, and its metabolites are predominantly excreted in bile (13) . Glibenclamide is a weak organic acid with a pKa (log of dissociation constant of acid) of 6.8 that dissociates to an organic anion at pH 7.4 (14) . Hepatic uptake of glibenclamide has been studied in rat hepatocytes and shown to be transported by facilitated diffusion through a sodium-and energy-independent carrier mechanism (15, 16) .
In the present study, we examined the role of Hnf-1␣ in the metabolism of glibenclamide. Our results indicate that loss of function of Hnf-1␣ has a profound effect on glibenclamide uptake by hepatocytes and leads to decreased clearance from the plasma. Elevated glibenclamide levels may therefore be responsible for the hypersensitivity of sulfonylureas in subjects with HNF-1␣ mutations.
RESEARCH DESIGN AND METHODS

Animals. Hnf-1␣ homozygous (Hnf-1␣
Ϫ/Ϫ ) mutants, heterozygotes (Hnf-1␣ ϩ/-), and wild-type (Hnf-1␣ ϩ/ϩ ) mice were maintained on a 12-h light/dark cycle with ad libitum access to water and a standard diet in the Laboratory of Animal Research Center, a pathogen-free animal facility at Rockefeller University. Hnf-1␣ Ϫ/Ϫ mice were generated in the laboratory of F. Gonzalez (National Institutes of Health, Bethesda, MD) (4 Ferre et al. (17) with the following modifications: 1) mice were anesthetized with Avertin (2.5 g 2,2,2-tribromoethanol in 1.5 ml tert-amylalcohol dissolved in 0.9% NaCl; dose 0.4 ml/25 g) and 2) their portal veins were cannulated and their livers were perfused with buffer A (10 mmol/l HEPES, 143 mmol/l NaCl, 7 mmol/l KCl, 0.2 mmol/l EDTA, pH 7.4), followed by buffer B (50 mmol/l HEPES, 100 mmol/l NaCl, 7 mmol/l KCl, 5 mmol/l CaCl 2 , pH 7.6), containing collagenase (0.5 mg/ml), at 37°C. After perfusion, the livers were excised, transferred to Dulbecco's modified Eagle's medium (DMEM), and cut into small pieces. The resulting cell suspension was passed through nylon mesh filters, centrifuged at 50g, and resuspended in DMEM, supplemented with 10% fetal bovine serum to inhibit residual collagenase activity. The hepatocytes were plated onto gelatin-coated plates at a density of 10 5 cells/cm 2 ; cultured in DMEM; supplemented with 10% fetal bovine serum, pyruvate (110 mg/ml), L-glutamine (2 mmol/l), penicillin, and streptomycin; and incubated at 37°C in 5% CO 2 atmosphere. The viability of the cells was tested with 0.4% trypan blue and was 80 -90%. Uptake experiments were performed within 24 h after the preparation of hepatocytes. Extraction and chromatographic separation. Extraction and chromatographic separation were performed according to Rydberg et al. (18) using a modified protocol. Briefly, for extraction, 500 mg liver tissue was homogenized in 2 ml PBS, and the cytosolic fraction was prepared by centrifugation at 14,000g for 10 min at 4°C. Serum was diluted with five volumes PBS before extraction. Then, 10% (vol/vol) of 2 mol/l HCl was added to cytosolic fraction or serum, and extraction was performed with six volumes n-hexane-dichloromethane (1:1, vol/vol) for 10 min at room temperature. The organic phase was transferred to a conical tube and evaporated to dryness at 37°C under a gentle stream of air, and the residue was dissolved in 80 l methanol.
Recoveries from liver and gut were 85 Ϯ 5% and from serum were 100 Ϯ 5%. For chromatographic separation of glibenclamide and its metabolites, a BioCad Perfusion Workstation (PerSeptive Biosystems) with a reverse-phase C 18 column (5 m, 4.6 mm ϫ 250 mm; Vydac) was used. The system was run at room temperature, and the mobile phase contained acetonitrile-PBS (28:72, vol/vol). The flow rate was 1 ml/min with pressures ranging from 11 to 17 MPa. Before separation, the system was equilibrated with a mobile phase for 1 h. A total of 20 l of the sample was injected, and 96 samples (0.2 ml) were collected starting at the time of injection. Radioactivity in all samples was measured by liquid scintillation counting. The recovery of radioactivity was 100 Ϯ 10%. Biochemical measurements. Protein concentrations were quantified by the bicinchoninic acid protein assay (Sigma) according to the manufacturer's instructions and using bovine serum albumin as a standard. Insulin concentrations were determined by a double-antibody radioimmunoassay (Linco, St. Louis, MO) using rat insulin as standard. Statistical analysis. Results are expressed as means Ϯ SE. Statistical analysis was performed by a two-tailed Student's t test for unpaired data. Differences were considered to be significant at P Ͻ 0.05.
RESULTS
Glibenclamide-induced insulin secretion in mutant
Hnf-1␣ mice. To assess sulfonylurea-induced insulin secretion in vivo, we administered glibenclamide (1 mg/kg body wt) intravenously and compared insulin secretion between wild-type mice, Hnf-1␣ ϩ/Ϫ mice, and their Hnf-1␣ Ϫ/Ϫ littermates. After glibenclamide injection, Hnf-1␣ ϩ/Ϫ mice exhibited insulin levels at 2, 5, 10, 30, and 60 min that were indistinguishable from those of wild-type animals. Furthermore, blood glucose levels did not differ in Hnf-1␣ ϩ/ϩ and Hnf-1␣ ϩ/Ϫ animals after intravenous glibenclamide administration. We then compared serum insulin levels after a glibenclamide challenge of Hnf-1␣
and Hnf-1␣ ϩ/ϩ animals. Fasting insulin levels from blood samples collected at Ϫ15 and 0 min were comparable between the two groups of mice (0.27 Ϯ 0.06 and 0.36 Ϯ 0.11 ng/ml in Hnf-1␣ ϩ/ϩ animals vs. 0.27 Ϯ 0.03 and 0.24 Ϯ 0.04 ng/ml in Hnf-1␣ Ϫ/Ϫ animals). Insulin levels at 2 min after glibenclamide were not decreased in Hnf-1␣ Ϫ/Ϫ mice (2.48 Ϯ 0.38 ng/ml) compared with Hnf-1␣ ϩ/ϩ mice (2.36 Ϯ 0.32 ng/ml). As shown in Fig. 1, a similar Fig. 3A . Glibenclamide uptake into primary hepatocytes from Hnf-1␣ Ϫ/Ϫ mice was markedly lower than that of the hepatocytes derived from Hnf-1␣ ϩ/ϩ livers. Kinetics parameters of glibenclamide uptake into cultured hepatocytes were determined using a Lineweaver-Burk plot analysis (data not shown). The calculated V max was 2.4-fold higher in Hnf-1␣ ϩ/ϩ hepatocytes than in Hnf-1␣ Ϫ/Ϫ hepatocytes (301 vs. 128 pmol ⅐ min Ϫ1 ⅐ mg Ϫ1 protein, respectively). These results demonstrate that differences in glibenclamide up- take were due to a primary effect and not secondary to a difference in serum composition between Hnf-1␣ ϩ/ϩ and Hnf-1␣ Ϫ/Ϫ mice. Furthermore, the data indicate that a decrease in hepatic transport and/or a defect in liver glibenclamide metabolism is responsible for the defect in clearance of glibenclamide in mutant Hnf-1␣ mice. (Fig. 4D) . These data suggest that glibenclamide itself, and not its metabolites, constitutes the majority of the plasma levels in Hnf-1␣ Ϫ/Ϫ mice. Furthermore, the presence of glibenclamide metabolites in the intestine of Hnf-1␣ Ϫ/Ϫ mice indicates that secretion of glibenclamide metabolites into the biliary system is functional. We therefore conclude that hepatic metabolism of glibenclamide as well as biliary secretion is functional in Hnf-1␣ Ϫ/Ϫ mice.
Glibenclamide metabolizing pathway is not altered in liver of
DISCUSSION
In this study, we examined the role of HNF-1␣ in glibenclamide metabolism to study possible mechanisms for hypersensitivity to sulfonylureas in HNF-1␣-dependent diabetes (MODY3). As a model system for MODY 3, we used mice in which the Hnf-1␣ gene was inactivated by targeted mutagenesis (4). Heterozygous Hnf-1␣ mice do 
DECREASED GLIBENCLAMIDE UPTAKE IN HNF-1␣
؊/؊ HEPATOCYTES not develop diabetes, and islets have normal insulin secretion in response to glucose and other insulin secretagogues (5, 19, 22) . Furthermore, we did not detect differences in insulin secretion or blood glucose levels after an intravenous glibenclamide infusion between wild-type and Hnf-1␣ ϩ/Ϫ mice, indicating that haplo-insufficient mice are not suitable for studying the pharmacogenetics of glibenclamide in Hnf-1␣ deficiency. However, Hnf-1␣ Ϫ/Ϫ mice are diabetic, and their pancreatic islets have profound defects in glucose-and arginine-stimulated insulin secretion (19) . Pancreatic islets from Hnf-1␣ Ϫ/Ϫ mice also exhibit significantly reduced insulin secretory responses to tolbutamide compared with Hnf-1␣ ϩ/Ϫ animals in vitro (5, 19) . However, in vivo, we have observed that insulin responses to glibenclamide are similar in Hnf-1␣
Ϫ/Ϫ and Hnf-1␣ ϩ/ϩ mice. This discrepancy may be explained by the increased glibenclamide concentration to which pancreatic islets of Hnf-1␣ Ϫ/Ϫ animals are exposed. Therefore, this finding suggests that ␤-cells that are deficient in Hnf-1␣ are normo-or hyposensitive to the actions of sulfonylureas, thus making it unlikely that a ␤-cell intrinsic mechanism is responsible for the increased sensitivity to sulfonylureas.
HNF-1␣ is expressed in the liver and the kidney-two organs that play a crucial role in the detoxification of glibenclamide. Therefore, we tested the hypothesis that hepatic metabolism is affected in Hnf-1␣ Ϫ/Ϫ mice. The elimination of glibenclamide from the body depends on hepatic metabolism and biliary clearance. In the liver, glibenclamide is converted into two major metabolites: 4-trans-hydroxyglibenclamide and 3-cis-hydroxyglibenclamide (18) . Approximately 50% of these compounds are excreted in the urine and 50% in the bile. The first step of glibenclamide metabolism involves the transport by an as yet unknown energy-independent facilitative diffusion process (15) . The uptake of glibenclamide can be inhibited by other organic anions including the unconjugated bile acid cholate, as well as loop diuretics such as bumetanide (20, 23, 24) . We have previously shown that Hnf-1␣ Ϫ/Ϫ mice have elevated serum bile acid levels due to increased de novo synthesis and decreased uptake by hepatocytes (21) . Therefore, the high levels of bile acids present in sera of Hnf-1␣ Ϫ/Ϫ mice could have contributed to the decreased clearance of glibenclamide observed in vivo. To control for these confounding factors, we studied glibenclamide uptake into cultured hepatocytes of Hnf-1␣ Ϫ/Ϫ and Hnf-1␣ ϩ/ϩ mice and showed that V max was approximately threefold lower in mutant mice. The results demonstrate that the decreased clearance of glibenclamide is caused by a primary defect in hepatic clearance.
Inactivation of glibenclamide in the liver occurs through hydroxylation by cytochrome P450 enzymes followed by glucuronoconjugation and sulfonoconjugation (23) . Thus, depending on the limiting step of glibenclamide metabolism, reduced uptake of glibenclamide into hepatocytes may be attributed to an impairment of hepatic uptake or metabolism. To investigate if hydroxylation of glibenclamide was impaired, we measured its metabolites in livers of Hnf-1␣ Ϫ/Ϫ and Hnf-1␣ ϩ/ϩ animals. Using HPLC analysis, we showed that the ratios of glibenclamide and its two hydroxylated metabolites 4-trans-hydroxyglibenclamide and 3-cis-hydroxyglibenclamide were significantly increased in liver extracts of Hnf-1␣ Ϫ/Ϫ mice compared with wild-type littermates. This result indicates that a defect in glibenclamide metabolism is not responsible for decreased glibenclamide uptake in hepatocytes of Hnf-1␣ Ϫ/Ϫ mice. Furthermore, the increase of the relative metabolite concentrations in liver extracts of Hnf-1␣ Ϫ/Ϫ mice may be due to the reduced glibenclamide concentrations in the hepatocytes of Hnf-1␣ Ϫ/Ϫ animals. Together, our data strongly suggest that decreased transport across the hepatocyte plasma membrane appears to be responsible for the increased biological half-life of glibenclamide in mice lacking Hnf-1␣.
Petzinger and Fü ckel (15) have shown that glibenclamide transport occurs through a carrier-mediated system. Several classes of transport systems have been described that mediate hepatic organic anion uptake mechanisms (25) . Organic anion transporter proteins play a critical role in this process by transporting a broad spectrum of substrates in a sodium-independent manner. We have recently shown that gene expression of oatp1 (Slc21a1), Lst-1 (Slc21a6), OATPD (SLC21A11), and oat2 are downregulated or absent in livers of Hnf-1␣ Ϫ/Ϫ mice (21). These carriers are candidates for facilitating the transport of glibenclamide across the hepatocyte membrane. We cannot rule out that an intracellular binding protein may be involved in glibenclamide hepatic uptake as well. Meanwhile, identification of the glibenclamide transporter or intracellular binding protein remains to be established.
An example of the genetic defect altering the pharmacological response to sulfonylurea in diabetes was described 20 years ago, and a monogenic control of tolbutamide metabolism in humans was proposed (26) . Our results are consistent with the mechanism described in this study. Scott and Pofferbarger (26) observed a ninefold variation in the rate of tolbutamide disappearance from plasma after intravenous administration in humans. This variation was characterized by a trimodal frequency distribution, suggestive of monogenic inheritance. The binding of tolbutamide to serum proteins was not correlated to the tolbutamide clearance. It was therefore proposed that the microsomal hepatic conversion of free tolbutamide to hydroxytolbutamide was the impaired step. However, this process can be viewed as two separate steps: first, removal of free tolbutamide from the blood by hepatocytes, and second, enzymatic conversion by hepatic microsomes. Therefore, genetic variation in genes encoding the Hnf-1␣-regulated glibenclamide transporter as well the sulfonylurea-metabolizing P450 enzymes may be responsible for differences in plasma half-lives and susceptibility to these drugs in the population.
Glibenclamide is one of the most widely used orally active sulfonylureas in the treatment of type 2 diabetes. Hypoglycemia is the most important and most often fatal adverse effect of sulfonylureas (23) . We propose that hypoglycemia may occur more frequently in subjects with HNF-1␣ deficiency treated with glibenclamide because of a delayed disappearance of the drug from the blood. Very low doses of short-acting sulfonylureas should therefore be used initially in the treatment of MODY3 patients, and these drugs should be discontinued in subjects with liver disease. Monitoring sulfonylurea plasma concentration in MODY3 patients may also be useful for avoiding hypoglycemia.
